These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23647298)

  • 21. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.
    Morinaga R; Okamoto I; Furuta K; Kawano Y; Sekijima M; Dote K; Satou T; Nishio K; Fukuoka M; Nakagawa K
    Lung Cancer; 2007 Dec; 58(3):411-3. PubMed ID: 17601631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
    Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
    Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract]   [Full Text] [Related]  

  • 27. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.
    Rosell R; Taron M; Reguart N; Isla D; Moran T
    Clin Cancer Res; 2006 Dec; 12(24):7222-31. PubMed ID: 17189393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic classification of lung cancer: toward a personalized treatment.
    Mlika M; Laabidi S; Afrit M; Boussen H; El Mezni F
    Tunis Med; 2015 Jun; 93(6):339-44. PubMed ID: 26644092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular profiling of non-small cell lung cancer].
    Gibault L; Cazes A; Narjoz C; Blons H
    Rev Pneumol Clin; 2014; 70(1-2):47-62. PubMed ID: 24566035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methodological recommendations for the diagnostics of EGFR gene mutations and ALK gene rearrangement in the selection of non-small-cell lung cancer patients to molecularly targeted therapies.
    Krawczyk P; Chorostowska-Wynimko J; Dziadziuszko R; Jassem J; Krzakowski M; Langfort R; Puacz E; Wasąg B; Wojas-Krawczyk K
    Pneumonol Alergol Pol; 2014; 82(5):437-44. PubMed ID: 25133812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The mouse as preclinical models of lung cancer].
    Francoz S; Mathiaux J; Dubus P
    Bull Cancer; 2012 Nov; 99(11):1017-27. PubMed ID: 23131302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging targeted therapies in non-small cell lung cancer.
    Khanal N; Ganti AK
    Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
    Rossi G; Graziano P; Leone A; Migaldi M; Califano R
    Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.